vimarsana.com
Home
Live Updates
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference : vimarsana.com
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
Related Keywords
United States ,
Spain ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Switzerland ,
America ,
Kevin Garey ,
Eugenie Basseres ,
Davidp Luci ,
Company Ph ,
Society Or Healthcare Epidemiology Of America ,
Global European Society Of Clinical Microbiology ,
Trial Oversight Committee ,
Data Monitoring Committee ,
Exchange Commission On Form ,
Infectious Diseases Society Of America ,
European Society Of Clinical Microbiology ,
Research Scientist ,
Acurx Pharmaceuticals ,
Nasdaq ,
Acurx Pharmaceuticals Inc ,
Company Scientific Advisory Board ,
University Of Houston College Pharmacy ,
Drug Administration ,
Exchange Commission ,
Prnewswire Acurx Pharmaceuticals Inc ,
European Society ,
Clinical Microbiology ,
Infectious Diseases ,
Houston College ,
Principal Investigator ,
Acurx Scientific Advisory Board ,
Double Blind Study ,
Ibezapolstat Compared ,
Executive Committee ,
Ibezapolstat Phase ,
Scientific Advisory Board ,
Clinical Cure ,
Modified Intent ,
Treat Population ,
Per Protocol Population ,
Prescribing Information ,
Independent Data Monitoring Committee ,
Gram Positive Selective Spectrum ,
Qualified Infectious Disease Product ,
Generating New Antibiotic Incentives Now ,
Clinical Practice Guidelines ,
Infectious Diseases Society ,
Healthcare Epidemiology ,
New England Journal ,
Bile Acid ,
Private Securities Litigation Reform Act ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.